The effects of coumadin on the prothrombin (factor II) coagulation pathway in man: relationship between antigen and activity levels.
作者信息
Lox C D, Maciulla G J, Heine M W, Messiha F S, Corrigan J J
出版信息
Proc West Pharmacol Soc. 1978;21:237-9.
PMID:693503
Abstract
摘要
相似文献
1
2
Warfarin therapy. 1.华法林治疗。1.
N Engl J Med. 1970 Sep 24;283(13):691-4. doi: 10.1056/NEJM197009242831307.
3
Problems of anticoagulation with warfarin in hyperthyroidism.甲状腺功能亢进症中使用华法林抗凝的问题。
Q J Med. 1986 Jan;58(225):43-51.
4
Influence of vinpocetine on warfarin-induced inhibition of coagulation.长春西汀对华法林诱导的凝血抑制作用的影响。
Int J Clin Pharmacol Ther Toxicol. 1990 Aug;28(8):323-8.
5
Studies on experimentally induced hypercoagulable state in rabbits.家兔实验性高凝状态的研究。
Thromb Diath Haemorrh. 1966 Jul 31;16(1):228-42.
6
Assessment of thrombogenicity of activated and non-activated prothrombin concentrates in a rat model.在大鼠模型中评估活化和未活化凝血酶原浓缩物的血栓形成倾向。
Br J Exp Pathol. 1986 Aug;67(4):597-604.
7
[Effect of nitro-- derivatives of warfarin on blood coagulation].
Farmakol Toksikol. 1967 Jul-Aug;30(4):456-60.
8
Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.通过放射免疫测定法检测因子IX抗原。华法林治疗患者及血友病B患者中的异常因子IX蛋白。
J Clin Invest. 1977 May;59(5):900-10. doi: 10.1172/JCI108712.
9
Usefulness of new analytical reagents demonstrated with coumadin-modified plasma.新型分析试剂在香豆素修饰血浆中的应用效果
Bibl Haematol. 1977;44:61-7. doi: 10.1159/000402151.
10
Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase.长期接受华法林治疗患者与初始阶段患者的血浆凝血酶原、因子VII及尿凝血酶原F1浓度比较
Am J Hematol. 1998 Mar;57(3):193-9. doi: 10.1002/(sici)1096-8652(199803)57:3<193::aid-ajh2>3.0.co;2-q.
Zotero 插件